NCT02134197View on ClinicalTrials.gov

Dose-escalation Study of Lupartumab Amadotin (BAY1129980)

PHASE1TerminatedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 22, 2014

Primary Completion Date

August 30, 2018

Study Completion Date

August 30, 2018

Conditions
Neoplasms
Interventions
DRUG

Lupartumab Amadotin (BAY1129980)

Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.

Trial Locations (15)

14263

Buffalo

19104

Philadelphia

27710

Durham

32610

Gainesville

37203

Nashville

66205

Westwood

75230

Dallas

77030

Houston

80045

Aurora

92093

La Jolla

94305

Stanford

20007-2197

Washington D.C.

07601

Hackensack

Unknown

New York

98109-1023

Seattle

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY